

Lifco Q1 2025 - So far, so good

Redeye updates its estimates and valuation following Lifco releasing its Q1 2025 report. Sales slightly beat our estimates on the back of solid organic growth, while mix effects resulted in a slight margin miss. Year-to-date M&A volume aligns with our projections. Myriad economic uncertainties continue to muddy Lifco's short-term outlook, though we remain confident in the company's long-term performance.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Lifco Q1 2025 - So far, so good